QRG Capital Management Inc. Reduces Holdings in Takeda Pharmaceutical Co. $TAK

QRG Capital Management Inc. lessened its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 35.0% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 281,143 shares of the company’s stock after selling 151,511 shares during the quarter. QRG Capital Management Inc.’s holdings in Takeda Pharmaceutical were worth $4,116,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE increased its stake in Takeda Pharmaceutical by 225.8% during the second quarter. Bank of America Corp DE now owns 1,037,163 shares of the company’s stock worth $16,035,000 after acquiring an additional 718,805 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after purchasing an additional 692,404 shares during the last quarter. Quantinno Capital Management LP grew its holdings in shares of Takeda Pharmaceutical by 54.5% during the 2nd quarter. Quantinno Capital Management LP now owns 797,036 shares of the company’s stock worth $12,322,000 after purchasing an additional 280,992 shares during the period. Brandes Investment Partners LP increased its position in shares of Takeda Pharmaceutical by 5.9% during the 2nd quarter. Brandes Investment Partners LP now owns 3,712,278 shares of the company’s stock worth $57,392,000 after purchasing an additional 208,136 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in Takeda Pharmaceutical by 210.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 264,092 shares of the company’s stock valued at $4,083,000 after buying an additional 179,108 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $16.15 on Monday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.37 and a quick ratio of 0.76. The company has a market cap of $51.39 billion, a P/E ratio of 201.88 and a beta of 0.03. The stock has a 50-day moving average of $14.93 and a two-hundred day moving average of $14.71. Takeda Pharmaceutical Co. has a 1-year low of $12.80 and a 1-year high of $16.48.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, October 30th. The company reported $0.44 EPS for the quarter, meeting the consensus estimate of $0.44. The business had revenue of $7.30 billion during the quarter, compared to analyst estimates of $8.01 billion. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on TAK shares. Morgan Stanley assumed coverage on shares of Takeda Pharmaceutical in a research note on Tuesday, January 13th. They set an “overweight” rating for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.